Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 14/20 | 0.78 |
| ▸ | ACR | P10323 | 11/20 | 0.78 |
| ▸ | F2 | P00734 | 4/20 | 0.75 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.75 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.75 |
| ▸ | HGFAC | Q04756 | 3/20 | 0.69 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.65 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.64 |
| ▸ | KLK1 | P06870 | 1/20 | 0.64 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008711 | 0.81 | PRSS1 (0.67) | PRSS1ACRF2TMPRSS2PLG | |
| SCHEMBL20008709 | 0.81 | PRSS1 (0.71) | PRSS1ACRF2PRSS2PRSS3 | |
| SCHEMBL20008700 | 0.79 | PRSS1 (0.88) | PRSS1ACRF2PRSS2PRSS3 | |
| SCHEMBL20008706 | 0.79 | PRSS1 (1.00) | PRSS1ACRF2PRSS2PRSS3 | |
| SCHEMBL18720310 | 0.77 | PRSS1 (0.59) | PRSS1ACRF2TMPRSS2PLG | |
| SCHEMBL30627528 | 0.76 | PLG (1.00) | PRSS1ACRF2PRSS2PRSS3 | |
| SCHEMBL20008755 | 0.76 | TMPRSS2 (0.66) | PRSS1ACRF2TMPRSS2PLG | |
| SCHEMBL20008707 | 0.76 | PRSS1 (0.71) | PRSS1ACRF2PRSS2PRSS3 | |
| SCHEMBL29358345 | 0.75 | HGFAC (1.00) | PRSS1ACRF2PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL30117920 | 0.74 | HGFAC (0.97) | PRSS1ACRF2PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885ACR 4881/4885F2 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.